Second-quarter earnings for the S&P 500 are expected to reach a two-year high. Given the strong earnings momentum, many investors would want to bet on earnings-focused ETFs.
The major index futures traded narrowly mixed early Friday as the imminent release of the June producer price inflation report kept traders on edge as they await confirmation that inflation is sustainably decreasing. After moving sharply to the downside, bond yields have begun ticking higher, but gold futures slipped.
Many investors are attracted by the prospect of strong returns from income doubling stocks. Doubling one's capital within a reasonable timeframe is undoubtedly an attractive proposition.
Building wealth takes time, but if you know where to park your money, you can make the most of your investments. The first half of 2024 was exceptional for the stock market, with several high-potential stocks hitting 52-week highs and the S&P 500 and Nasdaq steadily moving higher.
Identifying undervalued growth stocks to buy presents a compelling opportunity for savvy investors. Often overlooked or misunderstood by the broader market, these companies can potentially deliver outsized returns for investors.
The ETF train is well and truly streaming through the countryside, with assets rapidly accumulating for the vehicle. The ETF universe is vast and growing wider at an accelerating rate.
Wood added to her positions in Palantir, Archer Aviation, and Intellia Therapeutics on Monday. Palantir is one of her largest holdings, and the big data analytics specialist has more than quadrupled since the start of last year.
Disney stock is down after the proxy battle. The pullback offers a bargain opportunity to invest. Movies are back on track after a lackluster year (for Disney). Diversification allows other parts of the company to support struggling areas. This will smooth earnings when movies or streaming hit a profit bump.
Achieve Life Sciences, Inc. initiated an open-label ORCA-OL trial using cytisinicline for smoking cessation; the Efficacy of the drug already established in several prior studies. Alignment with FDA that successful completion of ORCA-OL trial is necessary for NDA filing of cytisinicline in the 1st half of 2025. The global smoking cessation product market is estimated to reach $69.8 billion by the end of 2034.
With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.
Gold steadied following a key U.S. inflation report that aligned with expectations, increasing hopes for a Federal Reserve rate cut by September.
Gulfport is now expected to generate close to $300 million in 2024 free cash flow. About three-quarters of this is driven by its hedges. Improved 2025 strip prices point to it potentially being able to generate $400 million in free cash flow before hedges then, with hedges boosting this to $440 million.